CoChat

Cellular and molecular mechanisms of metformin: an overview

Open access
Viollet, Benoit, Guigas, Bruno, Garcia, Nieves Sanz, Leclerc, Jocelyne, Foretz, Marc, Andreelli, Fabrizio · 2012 · Clinical Science

The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.

Abstract

Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first-line oral therapy for T2D (Type 2 diabetes). The main effect of this drug from the biguanide family is to acutely decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The demonstration that respiratory chain complex I, but not AMPK, is the primary target of metformin was recently strengthened by showing that the metabolic effect of the drug is preserved in liver-specific AMPK-deficient mice. Beyond its effect on glucose metabolism, metformin has been reported to restore ovarian function in PCOS (polycystic ovary syndrome), reduce fatty liver, and to lower microvascular and macrovascular complications associated with T2D. Its use has also recently been suggested as an adjuvant treatment for cancer or gestational diabetes and for the prevention in pre-diabetic populations. These emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/cs20110386

Cites

167 of 167 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 1,720

Metadata

Authors
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F.
Affiliations
  • INSERM, U1016, Institut Cochin, Paris, France
  • Leiden University Medical Center (NL)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
  • Leclerc, Jocelyne
  • Foretz, Marc
Venue
Clinical Science
Published
2011-11-11
Volume
122
Issue
6
Pages
253-270
ISSN
  • 0143-5221 (ISSN-L)
  • 1470-8736
OpenAlex
W2154024784
Cited by
1,720
References
167
Citations by year
2026: 63 · 2025: 85 · 2024: 96 · 2023: 103 · 2022: 106 · 2021: 143 · 2020: 155 · 2019: 135 · 2018: 141 · 2017: 156 · 2016: 137 · 2015: 144 · 2014: 117 · 2013: 104 · 2012: 34
FWCI
7.43
Type
journal article
Language
en
Open access
Locations
  • Clinical Science (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • Leiden Repository (Leiden University) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
metformin, type 2 diabetes, biguanides, AMPK, mitochondrial complex I inhibition, hepatic gluconeogenesis, hepatic glucose production, polycystic ovary syndrome, hepatic steatosis, diabetes complications, adjuvant cancer therapy, gestational diabetes mellitus, prediabetes, pharmacogenetics, personalized medicine
MeSH terms
Animals, Cardiovascular System, Diabetic Nephropathies, Female, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Polycystic Ovary Syndrome, Circadian Clocks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.